Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)‘s stock had its “buy” rating reissued by stock analysts at Noble Financial in a note issued to investors on Wednesday.

Several other research firms have also recently weighed in on CRBP. Cantor Fitzgerald set a $24.00 price target on Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a report on Monday, July 17th. BidaskClub upgraded Corbus Pharmaceuticals Holdings from a “sell” rating to a “hold” rating in a report on Saturday, July 8th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $20.50.

Corbus Pharmaceuticals Holdings (CRBP) opened at 6.10 on Wednesday. The firm’s market capitalization is $306.33 million. The firm’s 50-day moving average is $6.26 and its 200-day moving average is $7.12. Corbus Pharmaceuticals Holdings has a 52-week low of $2.86 and a 52-week high of $10.78.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). The company had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $2.50 million. Corbus Pharmaceuticals Holdings had a negative return on equity of 117.78% and a negative net margin of 874.41%. On average, equities analysts expect that Corbus Pharmaceuticals Holdings will post ($0.77) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/09/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-receives-buy-rating-from-noble-financial.html.

Several hedge funds have recently added to or reduced their stakes in the company. KCG Holdings Inc. boosted its stake in Corbus Pharmaceuticals Holdings by 1,066.5% in the first quarter. KCG Holdings Inc. now owns 141,209 shares of the biopharmaceutical company’s stock valued at $1,165,000 after buying an additional 129,104 shares during the period. Geode Capital Management LLC boosted its stake in Corbus Pharmaceuticals Holdings by 16.5% in the first quarter. Geode Capital Management LLC now owns 201,177 shares of the biopharmaceutical company’s stock valued at $1,659,000 after buying an additional 28,492 shares during the period. Vanguard Group Inc. boosted its stake in Corbus Pharmaceuticals Holdings by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,255,429 shares of the biopharmaceutical company’s stock valued at $10,357,000 after buying an additional 71,419 shares during the period. Segantii Capital Management Ltd boosted its stake in Corbus Pharmaceuticals Holdings by 683.3% in the first quarter. Segantii Capital Management Ltd now owns 56,400 shares of the biopharmaceutical company’s stock valued at $465,000 after buying an additional 49,200 shares during the period. Finally, Laurion Capital Management LP purchased a new stake in Corbus Pharmaceuticals Holdings during the first quarter valued at $1,015,000. Institutional investors own 28.12% of the company’s stock.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.